WEKO3
アイテム
{"_buckets": {"deposit": "a71842fc-f503-4d28-b36d-727610d23012"}, "_deposit": {"created_by": 1, "id": "64585", "owners": [1], "pid": {"revision_id": 0, "type": "depid", "value": "64585"}, "status": "published"}, "_oai": {"id": "oai:repo.qst.go.jp:00064585", "sets": ["29"]}, "author_link": ["636510", "636514", "636509", "636517", "636513", "636511", "636515", "636518", "636516", "636512"], "item_10005_date_7": {"attribute_name": "発表年月日", "attribute_value_mlt": [{"subitem_date_issued_datetime": "2012-04-27", "subitem_date_issued_type": "Issued"}]}, "item_10005_description_5": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Therapeutic outcome of hypofractionated conformal carbon ion radiotherapy towards localized prostate cancer was investigated. We analyzed the biochemical relapse-free rate of 1,084 cases which were observed for 6 months or more after carbon ion radiotherapy at the time of February 2011, also we analyzed survival rate, and the incidence of toxicity. 5-year biochemical relapse-free rate of whole cases was 90.6%. The Gleason score, PSA value and clinical stage were the significant prognostic factor of relapse-free rate. The difference of relapse-free rate by method of fractionation (20 fractions and 16 fractions) was not found. None but one out of 1,005 cases who were followed up at least 1 year developed grade 3 lower urological impairment, and incidences of grade 2 were 5.6% in lower urinary tract and 2.3% in the rectum, respectively. Furthermore, in the 16 fractions, the toxicity incidence was lower than 20 fractions. Accordingly, hypofractionation made it possible to reduce the toxicity incidence without reducing the relapse-free rate.", "subitem_description_type": "Abstract"}]}, "item_10005_description_6": {"attribute_name": "会議概要(会議名, 開催地, 会期, 主催者等)", "attribute_value_mlt": [{"subitem_description": "New Frontiers in Cancer Treatment", "subitem_description_type": "Other"}]}, "item_access_right": {"attribute_name": "アクセス権", "attribute_value_mlt": [{"subitem_access_right": "metadata only access", "subitem_access_right_uri": "http://purl.org/coar/access_right/c_14cb"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Tsuji, Hiroshi"}], "nameIdentifiers": [{"nameIdentifier": "636509", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Mizoguchi, Nobutaka"}], "nameIdentifiers": [{"nameIdentifier": "636510", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Toyama, Shingo"}], "nameIdentifiers": [{"nameIdentifier": "636511", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kamada, Tadashi"}], "nameIdentifiers": [{"nameIdentifier": "636512", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tsujii, Hirohiko"}], "nameIdentifiers": [{"nameIdentifier": "636513", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "辻 比呂志", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "636514", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "溝口 信貴", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "636515", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "戸山 真吾", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "636516", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "鎌田 正", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "636517", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "辻井 博彦", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "636518", "nameIdentifierScheme": "WEKO"}]}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "conference object", "resourceuri": "http://purl.org/coar/resource_type/c_c94f"}]}, "item_title": "Carbon Ion Radiotherapy for prostate cancer", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Carbon Ion Radiotherapy for prostate cancer"}]}, "item_type_id": "10005", "owner": "1", "path": ["29"], "permalink_uri": "https://repo.qst.go.jp/records/64585", "pubdate": {"attribute_name": "公開日", "attribute_value": "2012-05-11"}, "publish_date": "2012-05-11", "publish_status": "0", "recid": "64585", "relation": {}, "relation_version_is_last": true, "title": ["Carbon Ion Radiotherapy for prostate cancer"], "weko_shared_id": -1}
Carbon Ion Radiotherapy for prostate cancer
https://repo.qst.go.jp/records/64585
https://repo.qst.go.jp/records/64585ca46df8a-9fea-4745-b50c-d8f0e211e60d
Item type | 会議発表用資料 / Presentation(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2012-05-11 | |||||
タイトル | ||||||
タイトル | Carbon Ion Radiotherapy for prostate cancer | |||||
言語 | ||||||
言語 | eng | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_c94f | |||||
資源タイプ | conference object | |||||
アクセス権 | ||||||
アクセス権 | metadata only access | |||||
アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
著者 |
Tsuji, Hiroshi
× Tsuji, Hiroshi× Mizoguchi, Nobutaka× Toyama, Shingo× Kamada, Tadashi× Tsujii, Hirohiko× 辻 比呂志× 溝口 信貴× 戸山 真吾× 鎌田 正× 辻井 博彦 |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Therapeutic outcome of hypofractionated conformal carbon ion radiotherapy towards localized prostate cancer was investigated. We analyzed the biochemical relapse-free rate of 1,084 cases which were observed for 6 months or more after carbon ion radiotherapy at the time of February 2011, also we analyzed survival rate, and the incidence of toxicity. 5-year biochemical relapse-free rate of whole cases was 90.6%. The Gleason score, PSA value and clinical stage were the significant prognostic factor of relapse-free rate. The difference of relapse-free rate by method of fractionation (20 fractions and 16 fractions) was not found. None but one out of 1,005 cases who were followed up at least 1 year developed grade 3 lower urological impairment, and incidences of grade 2 were 5.6% in lower urinary tract and 2.3% in the rectum, respectively. Furthermore, in the 16 fractions, the toxicity incidence was lower than 20 fractions. Accordingly, hypofractionation made it possible to reduce the toxicity incidence without reducing the relapse-free rate. | |||||
会議概要(会議名, 開催地, 会期, 主催者等) | ||||||
内容記述タイプ | Other | |||||
内容記述 | New Frontiers in Cancer Treatment | |||||
発表年月日 | ||||||
日付 | 2012-04-27 | |||||
日付タイプ | Issued |